Physician, Patient and Caregiver Concordance in a Real-World US Generalized Myasthenia Gravis Population
Author(s)
Lesley-Ann Miller-Wilson, PhD1, Joe Conyers, MSc2, Shiva Lauretta Birija, BSc2, Hannah Connolly, MChem2, Gregor Gibson, BSc2, Lincy Lal, PharmD, PhD1, Yuriy Edwards, MD, PhD1.
1Immunovant, Inc., New York, NY, USA, 2Adelphi Real World, Bollington, United Kingdom.
1Immunovant, Inc., New York, NY, USA, 2Adelphi Real World, Bollington, United Kingdom.
Presentation Documents
OBJECTIVES: To explore concordance between physicians, patients with generalized myasthenia gravis (gMG), and caregivers with respect to patient quality of life (QoL), symptomology, and treatment satisfaction.
METHODS: Data were from the Adelphi gMG II Disease Specific Programme™, a cross-sectional survey conducted from February-August 2024. Neurologists, patients with gMG, and caregivers independently provided data. Outcomes were examined within matched physician-to-patient (PhysPat) and physician-to-caregiver (PhysCare) samples.
RESULTS: There were 37 PhysPat matches (54.1% female; mean [SD] age, 59.1 [11.2] years; mean [SD] time since diagnosis, 5.8 [4.8] years) and 23 PhysCare matches (69.6% female, mean [SD] age, 46.1 [13.0] years; mean [SD] time since diagnosis, 3.4 [2.5] years). Overall patient QoL was reported as “good” or “very good” by 70.2% of physicians and 54.0% of patients in the PhysPat sample, and by 56.5% of physicians and 52.1% caregivers in the PhysCare sample. Patient physical fatigue was reported by 40.5% of PhysPat physicians vs 62.9% of patients; in the PhysCare sample, 43.5% of physicians vs 82.6% of caregivers reported patient physical fatigue. Diplopia was reported in 78.4% of patients by PhysPat physicians vs 62.9% of matched patients; in the PhysCare sample, 78.3% of physicians and 56.5% of caregivers reported patient diplopia. Treatment prescriptions were reported by 97.3% of physicians in the PhysPat sample; of those, 25.0% reported prescriptions for complement inhibitors or neonatal fragment crystallizable receptor inhibitors. Corresponding findings in the PhysCare sample were 65.2% and 53.3%, respectively. Treatment satisfaction was reported as “neutral” or “dissatisfied” by 13.9% of physicians and 19.5% of patients in the PhysPat sample, and by 26.6% of both physicians and caregivers in the PhysCare sample.
CONCLUSIONS: Discordant reporting of QoL and symptoms suggests improvement is needed in the communication between physicians, patients, and caregivers. More targeted therapies are needed to optimize patient care and improve treatment satisfaction.
METHODS: Data were from the Adelphi gMG II Disease Specific Programme™, a cross-sectional survey conducted from February-August 2024. Neurologists, patients with gMG, and caregivers independently provided data. Outcomes were examined within matched physician-to-patient (PhysPat) and physician-to-caregiver (PhysCare) samples.
RESULTS: There were 37 PhysPat matches (54.1% female; mean [SD] age, 59.1 [11.2] years; mean [SD] time since diagnosis, 5.8 [4.8] years) and 23 PhysCare matches (69.6% female, mean [SD] age, 46.1 [13.0] years; mean [SD] time since diagnosis, 3.4 [2.5] years). Overall patient QoL was reported as “good” or “very good” by 70.2% of physicians and 54.0% of patients in the PhysPat sample, and by 56.5% of physicians and 52.1% caregivers in the PhysCare sample. Patient physical fatigue was reported by 40.5% of PhysPat physicians vs 62.9% of patients; in the PhysCare sample, 43.5% of physicians vs 82.6% of caregivers reported patient physical fatigue. Diplopia was reported in 78.4% of patients by PhysPat physicians vs 62.9% of matched patients; in the PhysCare sample, 78.3% of physicians and 56.5% of caregivers reported patient diplopia. Treatment prescriptions were reported by 97.3% of physicians in the PhysPat sample; of those, 25.0% reported prescriptions for complement inhibitors or neonatal fragment crystallizable receptor inhibitors. Corresponding findings in the PhysCare sample were 65.2% and 53.3%, respectively. Treatment satisfaction was reported as “neutral” or “dissatisfied” by 13.9% of physicians and 19.5% of patients in the PhysPat sample, and by 26.6% of both physicians and caregivers in the PhysCare sample.
CONCLUSIONS: Discordant reporting of QoL and symptoms suggests improvement is needed in the communication between physicians, patients, and caregivers. More targeted therapies are needed to optimize patient care and improve treatment satisfaction.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
PCR233
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Neurological Disorders